The Future Role of Bispecific Antibodies in Lymphoma

H&O What is the mechanism of action of bispecific antibodies? JA Bispecific antibodies aim to harness the power of the immune system. These treatments are monoclonal […]

Evolving Third-Line Treatment Options for Follicular Lymphoma

H&O What led to the recent withdrawals of phosphoinositide 3-kinase (PI3K) inhibitors in the setting of follicular lymphoma? JB In the past few months, several PI3K […]

Highlights in Leukemia and Lymphoma From the 63rd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 63rd ASH Meeting and Exposition December 11-14, 2021 • Atlanta, Georgia The Combination of Umbralisib Plus Ublituximab Is Active […]

Evolving Management of Patients With Double-Hit Lymphoma

H&O What is the definition of double-hit lymphoma? AL Double-hit lymphoma is an aggressive B-cell lymphoma with MYC translocation and a BCL2 and/or BCL6 translocation. The […]

Umbralisib and Ublituximab: An Upcoming Regimen for Chronic Lymphocytic Leukemia

H&O What types of drugs are umbralisib and ublituximab? JG Umbralisib (Ukoniq, TG Therapeutics) is a phosphoinositide 3 (PI3) kinase delta inhibitor. Umbralisib is approved for […]

Highlights in Mantle Cell Lymphoma From the 62nd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the All-Virtual 62nd ASH Meeting and Exposition • December 5-8, 2020 Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell […]

Highlights in Hodgkin Lymphoma From the 62nd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the All-Virtual 62nd ASH Meeting and Exposition • December 5-8, 2020 Frontline Brentuximab Vedotin as Monotherapy or in Combination for […]

Highlights in Relapsed/Refractory Follicular Lymphoma From the 62nd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the All-Virtual 62nd ASH Meeting and Exposition • December 5-8, 2020 Analyzing Efficacy Outcomes From the Phase 2 Study […]

Refining the Management of Relapsed or Refractory Follicular Lymphoma

Abstract: In patients with follicular lymphoma, the prolonged clinical course consisting of multiple relapses is a fundamental challenge that requires clinicians to consider how to best balance […]

Highlights in Mantle Cell Lymphoma From the 2020 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2020 ASCO Meeting Safety of Acalabrutinib Monotherapy in Hematologic Malignancies: Pooled Analysis From Clinical Trials Bruton tyrosine kinase […]

Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Brentuximab Vedotin With Chemotherapy for Stage 3/4 […]

Advances in Aggressive Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Rituximab Maintenance for Patients With Diffuse […]

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting

A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California 2-Year Follow-Up and High-Risk […]

Highlights in Cutaneous T-Cell Lymphoma From the 60th American Society of Hematology Annual Meeting

A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California Efficacy of Mogamulizumab […]

Highlights in Lymphoma From the 60th American Society of Hematology Annual Meeting

A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California The ECHELON-2 Trial: […]

Hem/Onc News

Duvelisib Approved in Relapsed/Refractory CLL, SLL, and FL The US Food and Drug Administration (FDA) approved duvelisib (Copiktra, Verastem) on September 24 for adults with relapsed […]

Immune-Mediated Hemolytic Anemia and Thrombocytopenia in Clonal B-Cell Disorders: A Review

Abstract: Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia purpura (ITP) have been associated with B-cell lymphoproliferative disorders. Here, we review the epidemiology, pathogenesis, diagnosis, and […]

Advances in Aggressive Lymphoma From the 2018 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2018 American Society of Clinical Oncology Annual Meeting • June 1-5, 2018 • Chicago, Illinois Special Reporting on: • […]

Highlights in Lymphoma From the 2018 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2018 American Society of Clinical Oncology Annual Meeting • June 1-5, 2018 • Chicago, Illinois Special Reporting on: • […]

Management of Relapsed/Refractory Follicular Lymphoma

• How I Treat Relapsed/Refractory Follicular Lymphoma: An Expert Perspective • Highlights from: The 2017 American Society of Hematology Annual Meeting and Exposition • December 9-12, 2017 […]